Literature DB >> 34471997

Clinical management of amyloid cardiomyopathy.

Morris M Kim1, Clinton M Kolseth1, Dayna Carlson1, Ahmad Masri2.   

Abstract

Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy. In this review, we review the role of routine medical therapy in amyloid cardiomyopathy, from heart failure management to orthostatic hypotension, atrial arrhythmias, thromboembolic complications, and prevention of sudden death. We conclude by discussing approaches to patients with end-stage disease.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Amyloidosis; Atrial fibrillation; Heart failure; Orthostatic hypotension; Restrictive cardiomyopathy; Sudden cardiac death

Mesh:

Year:  2021        PMID: 34471997     DOI: 10.1007/s10741-021-10159-w

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  71 in total

Review 1.  2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

2.  Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.

Authors:  Bishoy Abraham; Michael Megaly; Mina Sous; Mina Fransawyalkomos; Marwan Saad; Robert Fraser; Joel Topf; Steven Goldsmith; Mengistu Simegn; Bradley Bart; Zain Azzo; Nancy Mesiha; Rajaninder Sharma
Journal:  Am J Cardiol       Date:  2019-10-10       Impact factor: 2.778

3.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study.

Authors:  B L Kramer; B M Massie; N Topic
Journal:  Circulation       Date:  1983-04       Impact factor: 29.690

5.  Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine.

Authors:  B E Griffiths; P Hughes; R Dowdle; M R Stephens
Journal:  Thorax       Date:  1982-09       Impact factor: 9.139

6.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

Authors:  William T Abraham; Philip B Adamson; Robert C Bourge; Mark F Aaron; Maria Rosa Costanzo; Lynne W Stevenson; Warren Strickland; Suresh Neelagaru; Nirav Raval; Steven Krueger; Stanislav Weiner; David Shavelle; Bradley Jeffries; Jay S Yadav
Journal:  Lancet       Date:  2011-02-19       Impact factor: 79.321

7.  Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Authors:  James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

8.  Hemodynamic and regional blood flow response to captopril in congestive heart failure.

Authors:  T B Levine; M T Olivari; J N Cohn
Journal:  Am J Med       Date:  1984-05-31       Impact factor: 4.965

9.  Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis.

Authors:  Michele Boldrini; Francesco Salinaro; Roberta Mussinelli; Ambra Raimondi; Alessio Alogna; Francesco Musca; Giovanni Palladini; Giampaolo Merlini; Stefano Perlini
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

10.  Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy.

Authors:  A R Bengur; R H Beekman; A P Rocchini; D C Crowley; M A Schork; A Rosenthal
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.